Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: A systematic review and meta-analysis of observational studies

Gynecologic Oncology

Volumn 140, Issue 2, 2016, Pages 352-358

  Verdoodt, Freija ^a   Friis, Søren ^a,b   Dehlendorff, Christian ^a   Albieri, Vanna ^a   Kjaer, Susanne K ^a,b  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aspirin; Cancer prevention; Endometrial cancer; Non steroidal anti inflammatory drugs; Pharmacoepidemiology

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; ACETYLSALICYLIC ACID;

BIBLIOGRAPHIC DATABASE; BODY MASS; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DATA EXTRACTION; DISEASE ASSOCIATION; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; ENDOMETRIAL NEOPLASMS; OBSERVATIONAL STUDY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84961958209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.12.009     Document Type: Review

References (62)

1. J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J.W. Coebergh, and et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 Eur. J. Cancer 49 2013 1374 1403 10.1016/j.ejca.2012.12.027
2. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, and et al. Global cancer statistics, 2012 CA Cancer J. Clin. 65 2015 87 108 10.3322/caac.21262
3. C.M. Ulrich, J. Bigler, and J.D. Potter Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat. Rev. Cancer 6 2006 130 140 10.1038/nrc1801
4. J. Cuzick, F. Otto, J.A. Baron, P.H. Brown, J. Burn, and et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol. 10 2009 501 507 10.1016/s1470-2045(09)70035-x
5. J. Cuzick, M.A. Thorat, C. Bosetti, P.H. Brown, J. Burn, and et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population Ann. Oncol. 26 2015 47 57 10.1093/annonc/mdu225
6. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
7. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
8. D. Schottenfeld, and J. Beebe-Dimmer Chronic inflammation: a common and important factor in the pathogenesis of neoplasia CA Cancer J. Clin. 56 2006 69 83
9. G.A. Green Understanding NSAIDs: from aspirin to cox-2 Clin. Cornerstone 3 2001 50 60
10. S. Friis, A.H. Riis, R. Erichsen, J.A. Baron, and H.T. Sorensen Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study Ann. Intern. Med. 163 2015 347 355 10.7326/m15-0039
11. P.M. Rothwell, J.F. Price, F.G.R. Fowkes, A. Zanchetti, M.C. Roncaglioni, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612 10.1016/S0140-6736(11)61720-0
12. A.M. Algra, and P.M. Rothwell Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials Lancet Oncol. 13 2012 518 527 10.1016/S1470-2045(12)70112-2
13. C. Bosetti, V. Rosato, S. Gallus, J. Cuzick, and C. La Vecchia Aspirin and cancer risk: a quantitative review to 2011 Ann. Oncol. 23 2012 1403 1415 10.1093/annonc/mds113
14. J. Burn, A.M. Gerdes, F. Macrae, J.P. Mecklin, G. Moeslein, and et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the capp2 randomised controlled trial Lancet 378 2011 2081 2087 10.1016/s0140-6736(11)61049-0
15. P.M. Rothwell, M. Wilson, C.E. Elwin, B. Norrving, A. Algra, and et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750 10.1016/s0140-6736(10)61543-7
16. A. Bruno, M. Dovizio, S. Tacconelli, and P. Patrignani Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract Best Pract. Res. Clin. Gastroenterol. 26 2012 e1 e13 10.1016/j.bpg.2012.10.001
17. P.M. Rothwell, M. Wilson, J.F. Price, J.F. Belch, T.W. Meade, and et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials Lancet 379 2012 1591 1601 10.1016/s0140-6736(12)60209-8
18. P.M. Rothwell, F.G.R. Fowkes, J.F.F. Belch, H. Ogawa, C.P. Warlow, and et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41 10.1016/S0140-6736(10)62110-1
19. G. Kilic, B. Gurates, J. Garon, H. Kang, B. Arun, and et al. Expression of cyclooxygenase-2 in endometrial adenocarcinoma Eur. J. Gynaecol. Oncol. 26 2005 271 274
20. P. Knapp, A. Chabowski, A. Blachnio-Zabielska, M. Walentowicz-Sadlecka, M. Grabiec, and et al. Expression of estrogen receptors (alpha, beta), cyclooxygenase-2 and aromatase in normal endometrium and endometrioid cancer of uterus Adv. Med. Sci. 58 2013 96 103 10.2478/v10039-012-0055-1
21. Q.J. Cao, M.H. Einstein, P.S. Anderson, C.D. Runowicz, R. Balan, and et al. Expression of cox-2, ki-67, cyclin d1, and p21 in endometrial endometrioid carcinomas Int. J. Gynecol. Pathol. 21 2002 147 154
22. G. Ferrandina, F. Legge, F.O. Ranelletti, G.F. Zannoni, N. Maggiano, and et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome Cancer 95 2002 801 807 10.1002/cncr.10736
23. J. Gao, K. Niwa, W. Sun, M. Takemura, Z. Lian, and et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells Cancer Sci. 95 2004 901 907
24. H.A. Arango, S. Icely, W.S. Roberts, D. Cavanagh, and J.L. Becker Aspirin effects on endometrial cancer cell growth Obstet. Gynecol. 97 2001 423 427
25. M.A. Gates, S.S. Tworoger, A.H. Eliassen, S.A. Missmer, and S.E. Hankinson Analgesic use and sex steroid hormone concentrations in postmenopausal women Cancer Epidemiol. Biomark. Prev. 19 2010 1033 1041 10.1158/1055-9965.epi-09-0975
26. E.S. Diaz-Cruz, C.L. Shapiro, and R.W. Brueggemeier Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells J. Clin. Endocrinol. Metab. 90 2005 2563 2570 10.1210/jc.2004-2029
27. R. Kaaks, A. Lukanova, and M.S. Kurzer Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review Cancer Epidemiol. Biomark. Prev. 11 2002 1531 1543
28. M. Visser, L.M. Bouter, G.M. McQuillan, M.H. Wener, and T.B. Harris Elevated c-reactive protein levels in overweight and obese adults JAMA 282 1999 2131 2135
29. F. Modugno, R.B. Ness, C. Chen, and N.S. Weiss Inflammation and endometrial cancer: a hypothesis Cancer Epidemiol. Biomark. Prev. 14 2005 2840 2847 10.1158/1055-9965.epi-05-0493
30. A.E. Wallace, D.A. Gibson, P.T. Saunders, and H.N. Jabbour Inflammatory events in endometrial adenocarcinoma J. Endocrinol. 206 2010 141 157 10.1677/joe-10-0072
31. A.S. Neill, C.M. Nagle, M.M. Protani, A. Obermair, A.B. Spurdle, and et al. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis Int. J. Cancer 132 2013 1146 1155 10.1002/ijc.27717
32. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the prisma statement Int. J. Surg. 8 2010 336 341 10.1016/j.ijsu.2010.02.007
33. S. Sanderson, I.D. Tatt, and J.P. Higgins Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography Int. J. Epidemiol. 36 2007 666 676 10.1093/ije/dym018
34. S. Greenland, and K. O'Rourke On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions Biostatistics 2 2001 463 471 10.1093/biostatistics/2.4.463
35. G.A. Wells, B. Shea, D. O'Connell, J. Peterson, and V. Welch The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2004 Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
36. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
37. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 10.1136/bmj.327.7414.557
38. J.A.C. Sterne, D. Gavaghan, and M. Egger Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature J. Clin. Epidemiol. 53 2000 1119 1129 10.1016/S0895-4356(00)00242-0
39. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 10.1136/bmj.315.7109.629
40. A.K. Win, R. Chau, S.G. Dashti, D. Ait Ouakrim, D. Buchanan, and et al. Lifestyle modifiers of risk of endometrial cancer for women with germline mutations in DNA mismatch repair genes Int. J. Gynecol. Cancer 4 2014 1577 1578
41. S. Friis, H.T. Sorensen, J.K. McLaughlin, S.P. Johnsen, W.J. Blot, and et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin Br. J. Cancer 88 2003 684 688 10.1038/sj.bjc.6600760
42. H.T. Sorensen, S. Friis, B. Norgard, L. Mellemkjaer, W.J. Blot, and et al. Risk of cancer in a large cohort of nonaspirin nsaid users: a population-based study Br. J. Cancer 88 2003 1687 1692 10.1038/sj.bjc.6600945
43. A.I. Phipps, G.L. Anderson, B.B. Cochrane, C.I. Li, J. Wactawski-Wende, and et al. Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer Horm. Cancer 3 2012 240 248 10.1007/s12672-012-0117-7
44. T.M. Brasky, J. Liu, E. White, U. Peters, J.D. Potter, and et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the women's health initiative Int. J. Cancer 135 2014 1869 1883
45. F.M. Shebl, A.W. Hsing, Y. Park, A.R. Hollenbeck, L.W. Chu, and et al. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study PLoS One 9 2014 e114633 10.1371/journal.pone.0114633
46. K.N. Danforth, G.L. Gierach, L.A. Brinton, A.R. Hollenbeck, H.A. Katki, and et al. Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP diet and health study Cancer Prev. Res. (Phila.) 2 2009 466 472 10.1158/1940-6207.capr-08-0239
47. K.B. Moysich, J.A. Baker, K.J. Rodabaugh, and J.A. Villella Regular analgesic use and risk of endometrial cancer Cancer Epidemiol. Biomark. Prev. 14 2005 2923 2928 10.1158/1055-9965.epi-05-0457
48. C. Bodelon, J.A. Doherty, C. Chen, M.A. Rossing, and N.S. Weiss Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer Am. J. Epidemiol. 170 2009 1512 1517 10.1093/aje/kwp321
49. J. Fortuny, C. Sima, S. Bayuga, H. Wilcox, K. Pulick, and et al. Risk of endometrial cancer in relation to medical conditions and medication use Cancer Epidemiol. Biomark. Prev. 18 2009 1448 1456 10.1158/1055-9965.epi-08-0936
50. C. Bosetti, F. Bravi, R. Talamini, M. Montella, E. Negri, and et al. Aspirin and risk of endometrial cancer: a case-control study from Italy Eur. J. Cancer Prev. 19 2010 401 403
51. N. Brons, L. Baandrup, C. Dehlendorff, and S.K. Kjaer Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case-control study Cancer Causes Control 2015 10.1007/s10552-015-0578-4
52. D.M. Schreinemachers, and R.B. Everson Aspirin use and lung, colon, and breast cancer incidence in a prospective study Epidemiology 5 1994 138 146
53. A.N. Viswanathan, D. Feskanich, E.S. Schernhammer, and S.E. Hankinson Aspirin, nsaid, and acetaminophen use and the risk of endometrial cancer Cancer Res. 68 2008 2507 2513 10.1158/0008-5472.can-07-6257
54. A.E. Prizment, A.R. Folsom, and K.E. Anderson Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa women's health study Cancer Epidemiol. Biomark. Prev. 19 2010 435 442 10.1158/1055-9965.epi-09-0976
55. T.M. Brasky, K.B. Moysich, D.E. Cohn, and E. White Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the vitamins and lifestyle (vital) cohort Gynecol. Oncol. 128 2013 113 119 10.1016/j.ygyno.2012.10.005
56. V.W. Setiawan, R.K. Matsuno, G. Lurie, L.R. Wilkens, M.E. Carney, and et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the multiethnic cohort Cancer Epidemiol. Biomark. Prev. 21 2012 1441 1449 10.1158/1055-9965.epi-12-0390-t
57. M. Schmidt, J. Hallas, and S. Friis Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012 Clin. Epidemiol. 6 2014 155 168 10.2147/clep.s59156
58. N.R. Cook, I.M. Lee, J.M. Gaziano, D. Gordon, P.M. Ridker, and et al. Low-dose aspirin in the primary prevention of cancer: the women's health study: a randomized controlled trial JAMA 294 2005 47 55 10.1001/jama.294.1.47
59. N.R. Cook, I.M. Lee, S.M. Zhang, M.V. Moorthy, and J.E. Buring Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial Ann. Intern. Med. 159 2013 77 85 10.7326/0003-4819-159-2-201307160-00002
60. A. Bardia, J.O. Ebbert, R.A. Vierkant, P.J. Limburg, K. Anderson, and et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality J. Natl. Cancer Inst. 99 2007 881 889 10.1093/jnci/djk200
61. L. Baandrup, M.T. Faber, J. Christensen, A. Jensen, K.K. Andersen, and et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies Acta Obstet. Gynecol. Scand. 92 2013 245 255 10.1111/aogs.12069
62. R.I. Horwitz, and A.R. Feinstein The problem of «protopathic bias» in case-control studies Am. J. Med. 68 1980 255 258